As of Thursday close, Horizon Therapeutics Public Limited Company’s (NASDAQ:HZNP) stock was down -$0.08, moving down -0.07 percent to $112.74. The average number of shares traded per day over the past five days has been 3,395,060 shares. 3 times new highs have been achieved over the past 5 days, with a $6.40 gain in that time frame. In the last twenty days, the average volume was 1,988,515, while in the previous 50 days, it was 1,753,404.
Since last month, HZNP stock rose 13.87%. Shares of the company fell to $98.80 on 08/03/23, the lowest level in the past month. A 52-week high of $113.83 was reached on 08/30/23 after having rallying from a 52-week low of $57.84. Since the beginning of this year, HZNP’s stock price has dropped by -0.93% or -$1.06, and marked a new high 2 times. However, the stock has declined by -0.96% since its 52-week high.
HZNP stock investors should be aware that Horizon Therapeutics Public Limited Company (HZNP) stock had its last reported insider trading activity 227 days ago on Jan 17. Pasternak Andy, the EVP, Chief Strategy Officer of the company, disposed of 27,129 shares for $113.03 on Jan 17. It resulted in a $3,066,323 divestment by the insider. Cox Aaron sold 36,148 shares at an average price of $113.17 on Jan 13. The insider now owns 277 shares following the transaction. On Jan 11, EVP and Chief Medical Officer SHERMAN JEFFREY W sold 3,368 shares at $113.10 apiece. The transaction was valued at $380,921.
Valuation Metrics
Right now, Horizon Therapeutics Public Limited Company (HZNP) has a P/E ratio of about 60.26. The stock’s beta is 1.04. Besides these, the trailing price-to-sales (P/S) ratio of 7.06, the price-to-book (PB) ratio of 4.86, and the price-to-cash flow ratio of 26.86 may also be considered.
Financial Health
In the three months ended June 29, Horizon Therapeutics Public Limited Company’s quick ratio stood at 4.10, while its current ratio was 4.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.48, and the total debt-to-equity ratio was 0.48. On the profitability front, the trailing twelve-month gross margin is 75.20% percent. In the year ended June 29, EBITDA margin amounted to 30.09%, whereas operating margins totaled 14.10%. Based on annual data, HZNP earned $2.71 billion in gross profit and brought in $3.63 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.00%. Return on equity (ROE) for the past 12 months was 8.50%.
In Horizon Therapeutics Public Limited Company’s quarter-end financial report for June 29, it reported total debt of $2.54 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HZNP’s revenue rose 7.16% to $832.06 million during the quarter, while net income inched up to $944.0 million. While analysts expected Horizon Therapeutics Public Limited Company to report $1.03 quarterly earnings, the actual figure was $1.2 per share, beating the consensus estimate by 16.50%. During the quarter, the company generated $240.43 million in EBITDA. The liabilities of Horizon Therapeutics Public Limited Company were 3.99 billion at the end of its most recent quarter ended June 29, and its total debt was $2.73 billion. The value of shareholders’ equity is $229.0 million.
Technical Picture
This quick technical analysis looks at Horizon Therapeutics Public Limited Company’s (HZNP) price momentum. With a historical volatility rate of 22.36%, the RSI 9-day stood at 91.85% on 31 August.
With respect to its five-day moving average, the current Horizon Therapeutics Public Limited Company price is up by +6.02% percent or $6.40. At present, HZNP shares trade +13.90% above its 20-day simple moving average and +3.15% percent above its 100-day simple moving average. However, the stock is currently trading approximately +10.96% above its SMA50 and +51.86% above its SMA200.
Stochastic coefficient K was 91.75% and Stochastic coefficient D was 89.78%, while ATR was 1.43. Given the Stochastic reading of 90.46% for the 14-day period, the RSI (14) reading has been calculated as 85.95%. As of today, the MACD Oscillator reading stands at 3.87, while the 14-day reading stands at 5.61.
Analyst Ratings
H.C. Wainwright launched its rating on Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) to a Neutral in a note to investors on November 01, 2022. Horizon Therapeutics Public Limited Company (HZNP) has been rated Hold by analysts. According to 0 brokerage firms, HZNP is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Horizon Therapeutics Public Limited Company stock as buy, with 1 recommending it as overweight.
With a median target price of $116.50, the current consensus forecast for the stock is $116.50 – $116.50. Based on these forecasts, analysts predict Horizon Therapeutics Public Limited Company (HZNP) will achieve an average price target of $116.50.
